

INVESTMENT DIGEST

AI in PHARMA Q2 2021

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Q2 / 2021

Preclinical Development


Clinical Development

AI Companies - 300 Investors - 880 Corporations - 100

End-to-end Drug Development


Drug Repurposing


- AI Companies
- Investors
- Corporations



AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Q2 2021

AI Companies - 300
Investors - 880+
Corporations - 100





Link to Full Report: <https://www.deep-pharma.tech/investment-digest>

E-mail: info@deep-pharma.tech

Website: deep-pharma.tech

Deep Pharma Intelligence (DKA) Disclaimer.

The information and opinions in this report were prepared by Deep Pharma Intelligence. The information herein is believed by DKA to be reliable but DKA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. DKA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of DKA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of DKA and are subject to change without notice. DKA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.